Navigation Links
Besins Healthcare, Shin Nippon Biomedical Laboratories, Ltd Announce Delivery Technology Licensing Agreement for Intranasal Progesterone
Date:4/18/2013

BANGKOK, April 18, 2013 /PRNewswire-USNewswire/ -- Besins Healthcare (Besins) and Shin Nippon Biomedical Laboratories (SNBL), a global leader in hormonal products, announced today that they have completed a licensing agreement to use SNBL's proprietary intranasal drug delivery system, Muco™ System, to further develop its BHR-310 investigational agent containing progesterone for treating mild traumatic brain injury (TBI).

Under the terms of the licensing agreement, Besins gains access to SNBL's delivery technology, along with associated patents and know-how for delivery of progesterone.  Besins will be responsible for completing the development of the product, seeking regulatory approval and commercializing the product.  SNBL will be entitled to certain undisclosed milestone payments and royalties on sales.

"The overwhelming need for a treatment for concussions or mild TBI cannot be overstated," said Thomas W. MacAllister , JD, PhD, Besins Chief Development Officer.  "The condition is a huge unmet medical need, especially in theaters of war and on sports fields.  Partnering with SNBL will allow us to quickly accelerate our intranasal progesterone research program.  They have a tremendous amount of expertise in nasal delivery and the platform we are licensing gives far superior performance than the numerous other approaches we have tried."

An intranasal progesterone powder, BHR-310 is designed as a ready-for-use nasal spray treatment for wounded warriors or athletes with TBI at the site of injury.  Outcomes from preclinical studies of BHR-310 in rats and monkeys conducted by Besins' research and development affiliate, BHR Pharma, LLC, (BHR), support the feasibility of a high-dose, rapidly absorbed intranasal progesterone product able to deliver clinically meaningful doses of progesterone to the brain.  BHR anticipates entering the clinic in Q3 2013.

Progesterone (P4) belongs to a class of hormones called progestogens and is the major naturally occurring human progestogen.  A potent, naturally occurring neurosteroid hormone, P4 is produced in both male and female brains normally and in response to brain injury.  Research suggests that progesterone has a number of mechanisms of action through which it asserts neuroprotective effects by protecting or rebuilding the blood-brain barrier, decreasing development of cerebral edema (brain swelling), down-regulating the inflammatory cascade and limiting cellular necrosis and apoptosis (programmed cell death).[1]

"As we have seen in the preclinical phase, we expect that our Muco™ System will safely deliver therapeutic levels of progesterone, enabling the drug to be used in a broad population of brain injured patients," said Ryoichi Nagata , MD, PhD, SNBL President and CEO.  "We are pleased to partner with a company so dedicated to finding a viable treatment for this unmet medical condition. Establishment of this relationship is another important milestone in using Muco™ System to provide intranasal solutions to biopharmaceutical products.  With its versatility to deliver different types of compounds, we expect that there will be many more partnerships to follow."

Despite significant efforts and more than 75 clinical trials over the past 20 years, there is still no approved treatment for TBI.

About TBI
TBI is defined as an alteration in brain function, or other evidence of brain pathology, caused by an external force.[2]   According to the World Health Organization, the condition is the leading cause of death and disability in children and young adults worldwide and is involved in nearly half of all trauma deaths.  The U.S. Centers for Disease Control (CDC) calls TBI a "serious public health problem"[3]  and estimates that 3.5 million Americans suffer some form of TBI annually.  Of that number, approximately 75 percent of all TBIs are "concussions or other forms of mild TBI," according to the CDC.

TBI is roundly regarded as the "signature wound" of the Iraq and Afghanistan wars, accounting for 22 percent of all injuries and 59 percent of blast-related injuries.[4]  According to the Defense Centers of Excellence For Psychological Health and Traumatic Brain Injury, more than 230,000 American soldiers were diagnosed with TBI in the past decade.  Understanding about the devastating impact of the condition on athletes at all levels of competition is growing.  The University of Pittsburgh Department of Neurological Surgery estimates that in the United States, over 300,000 sports-related concussions occur annually, and the likelihood of suffering a concussion while playing a contact sport is estimated to be as high as 19 percent per year of play.

The CDC estimates that TBI's direct medical costs and indirect costs such as lost productivity total more than $75 billion annually in the United States.

About Besins Healthcare
Besins, a global leader in transdermal progesterone, estrogen and testosterone hormone therapy, is a fourth-generation, family-owned business headquartered in Bangkok, Thailand.  Its women's and men's healthcare products are available in 93 countries around the world.  Besins founded BHR Pharma, LLC in January 2008 as a wholly owned pharmaceutical research and development company.  Located near Washington, DC, USA, BHR is committed to bringing to market specialty treatments that employ non-oral delivery systems, with an emphasis on unmet and underserved medical needs.   BHR currently is running a 1180-patient study to test the efficacy and safety of Besins' proprietary intravenous progesterone formulation in patients suffering from severe traumatic brain injury.  Enrollment is expected to complete in Q3 of 2013.

About Shin Nippon Biomedical Laboratories
For more than 55 years, SNBL has been a leader in providing development services to biopharmaceutical companies, generating high quality data with the exceptional precision needed to rapidly advance new medical therapies and innovations that improve patients' lives. In addition to providing services, SNBL has a Translational Research business, which utilizes its development capabilities to develop value-adding technologies and provides them to the pharmaceutical and medical industry.  Under such business, SNBL has developed Muco™ System, a novel intranasal drug delivery technology platform, to provide effective delivery solutions to pharmaceutical products. 

[1] Stein DG, Wright DW, Kellerman AL (2008). Does progesterone have neuroprotective properties? Ann Emerg Med; 51(2): 164–72.

[2] Brain Injury Association of America - Retrieved on Aug. 3, 2012 from http://biausa.fyrian.com/about-brain-injury.htm#definitions

[3] Traumatic Brain Injury Center. (n.d.). Centers for Disease Control and Prevention. Retrieved May 1, 2012, from http://www.cdc.gov/traumaticbraininjury/

[4] "Injury to brain more than doubles Risk of later dementia," USA Today/Usaedition. Retrieved May 23, 2012 from http://www.usatoday.com/NEWS/usaedition/2011-07-18-Alz-brain-injury--_ST_U.htm


'/>"/>
SOURCE Besins Healthcare
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Save Up To 25% on International Biotech and Healthcare, and Pharmaceutical Conferences by Registering Through GII
2. Sentara Healthcare, MDLIVE Forge Unique Equity Partnership in Virtual Medicine
3. Global Healthcare, Regulatory and Reimbursement Landscape Forecasts and Trends in UAE, Canada and Taiwan
4. Scottsdale Healthcare, TGen study shows Abraxane/gemcitabine combination extends survival of pancreatic cancer patients
5. Global Image Sensor Market (2013 - 2018) By Technology (CCD, CMOS, Contact IS, Infrared, X-ray, FSI, BSI); Applications (Healthcare, Surveillance, Automobile, Consumer, Defense, Industrial); Geography (North America, Europe, APAC, ROW)
6. LodgeNet Healthcare, Siemens Partner To Deliver Bedside Environmental Controls For Maple Grove Hospital
7. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
8. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
9. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
10. Fluke Biomedical launches speedy new ProSim™ SPOT Light SpO2 Functional Tester
11. Fluke Biomedical device first to achieve environmentally-friendly label
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb 23, 2017 Research and Markets has ... Analysis and Strategies - 2016" report to their offering. ... The latest research ... drug pricing data and benchmarks in the global Autism Spectrum Disorder ... What are the key drugs marketed for Autism Spectrum ...
(Date:2/23/2017)... -- ITL Limited, ( ASX: ITD ), an innovative diversified healthcare ... ended 31 December 2016 compared with the previous corresponding period. A ... here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: 1.2 ... $15.7m; up 11%) Profit before tax of $2.12m ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Analysis and Strategies - 2016" report to their offering. ... The latest research ... pricing data and benchmarks in the global Oesophageal Cancer market. ... What are the key drugs marketed for Oesophageal Cancer and ...
Breaking Medicine Technology:
(Date:2/23/2017)... Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... first two episodes of WE TV’s “Mama June: From Not to Hot,” which will ... TV notable, “Mama” June Shannon, known to millions from the 2012 reality television series, ...
(Date:2/23/2017)... IPSWICH, Mass. (PRWEB) , ... February 23, 2017 ... ... chosen as an approved content provider for the National Institute for Health ... care and social care-related organizations in the National Health Service (NHS) to search, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink ... publication where generations converge and explore the world from different perspectives. By providing ... enables readers to gain understanding, increase empathy, and find greater happiness. , ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... the pre-eminent publication and community for those in the fight against cancer, has ... important in their success. HRA will release top-line findings in a webinar, ...
(Date:2/23/2017)... ... ... CALNOC, the nation’s first and only nursing quality indicators database today announced ... and Collaboration – in Seattle, WA on October 23, 2017. , Dr. Gary Kaplan ... Seattle since 2000. In addition to his role at Virginia Mason, Dr. Kaplan also ...
Breaking Medicine News(10 mins):